Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development ...
`
`Page 1 of 4
`
`MELDUNG EINSTELLEN ABO ÜBER PRESSEPORTAL.DE
`
`DEUTSCHLAND
`
`HOME
`
`THEMEN
`
`BLAULICHT
`
`Presseportal durchsuchen
`
`PAM PAM PAM! "SCHLAG DEN
`STAR" ÜBERZEUGT MIT SEHR...
`Unterföhring (ots) - Mr. Pam Pam Pam
`triumphiert über Dr. Kasalla in der bislang
`
`AMAZON PRIME VIDEO AB JETZT IN
`MEHR ALS 200 LÄNDERN UND...
`Seattle/München (ots) - Nach den USA,
`Großbritannien, Japan, Deutschland und
`
`"ROCKER IN DEUTSCHLAND":
`ZDFINFO ÜBER REBELLION UND...
`Mainz (ots) - Motorradclubs wie "Bandidos",
`"Hells Angels" oder "Osmanen Germania"
`
`GRÜNENTHAL GROUP
`
`Grünenthal has acquired US-based Thar
`Pharmaceuticals Inc. to expand its development
`portfolio of treatment options for CRPS (Complex
`Regional Pain Syndrome), a serious, disabling
`orphan disease
`
`16.11.2016 – 18:14
`
`Aachen, Germany / Pittsburgh, PA, USA (ots) -
`
`- The acquisition supports Grünenthal's commercial and R&D
`strategy to drive innovation in pain.
`- Thar Pharmaceutical's lead compound, T121, complements
`Grünenthal's existing development pipeline and the goal of
`delivering innovative and effective treatments to patients with
`CRPS.
`- Patients with Complex Regional Pain Syndrome (CRPS), an orphan
`disease, suffer from severe, persistent pain and a variety of
`other disabling symptoms.
`- There is a significant unmet medical need for those suffering
`from CRPS. Classic analgesics offer only limited symptomatic
`relief; there are no sufficiently effective treatment options
`available.
`- There are no FDA or EMA approved drug treatments for CRPS.
`
`Grünenthal, an R&D-driven, privately held international pharmaceutical company with
`headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-
`based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on
`transforming IV-only drugs into oral drugs for existing and new indications using its
`proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal
`has obtained the worldwide development and commercialization rights for Thar
`Pharmaceutical's lead development candidate, T121.
`
`T121 is a novel, Phase III-ready, composition-of-matter patented oral zoledronic acid drug
`product. It has received orphan drug designation by the U.S. Food and Drug Administration.
`T121 complements and broadens Grünenthal's portfolio for CRPS, which includes IV
`neridronate that is currently in phase III clinical development.
`
`Grünenthal will conduct clinical phase III development to demonstrate efficacy and safety of
`T121 for the treatment of patients with CRPS. Preclinical(1) and pilot clinical(2) evidence
`
`ZUM NEWSROOM
`
`NEWSROOM ABONNIEREN
`
`Abonnieren Sie alle Meldungen von
`Grünenthal Group
`
`Ihre E-Mail-Adresse
`
`ABONNIEREN
`
` TEILEN
`
` TWITTERN
`
`WEITERE
`
`Druckversion
`PDF-Version
`
`http://www.presseportal.de/pm/118252/3485652
`
`12/15/2016
`
`ANTECIP EXHIBIT 2004
`Grunenthal GmbH v. Antecip Bioventures II LLC
`PGR2019-00028
`
`

`

`Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development ...
`
`Page 2 of 4
`
`suggest that zoledronic acid could significantly reduce pain and other debilitating symptoms
`of CRPS.
`
`"Grünenthal is highly dedicated to improving the life of patients with pain and orphan diseases
`that have limited treatment options", said Gabriel Baertschi, CEO of the Grünenthal Group.
`"As global leader in pain, we strive to develop innovative, life-changing products. This
`acquisition fully supports our strategy to become a leading player in CRPS (Complex Regional
`Pain Syndrome)."
`
`"We are expanding our development portfolio for treating patients with orphan, disabling
`diseases. For CRPS, an often debilitating, extremely painful syndrome, truly efficacious
`treatments are lacking today", explained Dr. Klaus-Dieter Langner, Chief Scientific Officer of
`Grünenthal. "With the successful development of our expanded portfolio, oral T121 and IV
`neridronate, Grünenthal seeks to offer CRPS patients new hope for the future. Our teams are
`highly motivated and will use all of their knowledge, experience and resources to bring these
`promising treatments to market for patients as soon as possible."
`
`"We are very proud of what our team of employees, advisors, partners and investors has
`accomplished in driving our T121 lead product from an idea to the initiation of Phase 3
`development for the treatment of Complex Regional Pain Syndrome," stated the former Thar
`Pharmaceuticals board chairman, Dr. Lalit Chordia. Raymond K. Houck, former President and
`Chief Executive Officer of Thar Pharmaceuticals, added, "We believe Grünenthal is an
`exceptional strategic fit for Thar's T121. Grünenthal combines world-leading knowledge and
`expertise in CRPS with the resources, motivation and dedication to successfully develop and
`commercialize our potential first-in-class, non-opioid oral treatment to improve the lives of
`CRPS patients. Grünenthal's track record of bringing innovative pain treatments to patients
`around the globe underscores that we have chosen the right partner".
`
`Locust Walk acted as lead financial advisor to Thar on this transaction. SunTrust Robinson
`Humphrey, Inc. served as co-financial advisor to Thar, and Goodwin Procter LLP served as its
`legal advisor.
`
`About CRPS
`
`Complex Regional Pain Syndrome (CRPS) is a debilitating condition characterized by severe,
`continuous, burning or throbbing pain often occurring in an extremity after injury or surgery.
`The excessive pain is accompanied by changes in skin colour, temperature and/or
`swelling/edema. It is persistent, considered to be one of the most painful conditions, results in
`loss of physical function, and can lead to significant and sometimes permanent disability.
`There are currently no FDA- or EMA-approved treatments for CRPS.
`
`About Grünenthal
`
`The Grünenthal Group is an independent, family-owned, international research-based
`pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial
`specialist delivering true benefits to patients. By sustainably investing in research and
`development above the industrial average, we are committing to innovation in order to treat
`unmet medical needs and bring value-adding products to markets. Grünenthal is a fully
`integrated research & development company with a long track record of bringing innovative
`pain treatments and state-of-the-art technologies to patients. Altogether, the Grünenthal Group
`is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal
`products are sold in more than 155 countries and approx. 5,400 employees are working for the
`Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of EUR 1.2 bn. More
`information: www.grunenthal.com.
`
`http://www.presseportal.de/pm/118252/3485652
`
`12/15/2016
`
`

`

`Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development ...
`
`Page 3 of 4
`
`1 Wang et al, Anesth Analg. 2016 Oct;123(4):1033-45
`2 Zaspel, J. et.al., abstr. 93rd Meeting of Ger. Soc. Orthoped., Oct
`24-27, 2007, Berlin
`
`Contact:
`
`Steffen Fritzsche, Head Corporate Communications
`Tel.: +49 241 569-1335, Fax.: +49 241 569-51335,
`steffen.fritzsche@grunenthal.com
`
`Grünenthal GmbH,
`52099 Aachen, Germany,
`www.grunenthal.com
`
`Original-Content von: Grünenthal Group, übermittelt durch news aktuell
`
`THEMEN IN DIESER MELDUNG
`
`CRPS Medizin Gesundheit / Medizin Unternehmen Wirtschaft Pharmaindustrie
`Aachen, Germany / Pittsburgh, PA, USA
`
`Das könnte Sie auch interessieren:
`
`• Trendlines und B. Braun schließen
`Investitionsvereinbarung für Trendlines...
`• GSK auf Platz eins im Access-to-Medicine-
`Index 2016 / GSK führend beim...
`• BPI stellt Bildmaterial zur Geschäftsführung
`zur Verfügung
`• Data Presented at 12th European Congress
`on Epileptology (ECE) Offers New...
`• New Data for Fycompa® (perampanel) and
`Inovelon® (rufinamide) Further...
`
`• Arbeitgebervereinigung Nahrung und Genuss
`e. V. (ANG)
`• Casa Systems, Inc.
`• Atradius N.V.
`• KfW
`• SALESmanago
`• REWE Markt GmbH
`• BFFT Gesellschaft für Fahrzeugtechnik mbH
`• Volksbund Deutsche Kriegsgräberfürsorge
`
`• AIDS-Konferenz Durban
`• CRPS
`• Pharmaindustrie
`• Unternehmen
`• Medizin
`• Behinderte
`• Technik
`• Verteidigung
`
`Mit news aktuell erreichen Sie immer die richtigen Menschen
`
`Unser Verbreitungsnetzwerk ots sorgt für
`optimale Reichweite und Relevanz.
`
`Unsere Mediendatenbank zimpel bietet
`immer die richtigen Ansprechpartner in den
`Redaktionen.
`
`Die Presseportal App
`
`http://www.presseportal.de/pm/118252/3485652
`
`12/15/2016
`
`

`

`Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development ...
`
`Page 4 of 4
`
`IMPRESSUM
`NUTZUNGSRECHTE
`MEDIADATEN
`NEWSROOMS A-Z
`
`FÜR JOURNALISTEN
`TEXTVERSION
`SITEMAP
`FEEDS
`
`KONTAKT
`JOBS
`API
`DATENSCHUTZ
`
`http://www.presseportal.de/pm/118252/3485652
`
`12/15/2016
`
`